title: Dual antiplatelet therapy for coronary stenting: a clear path for a research agenda.
authors.forename: Jane A
authors.initials: JA
authors.lastname: Leopold
authors.forename: Elliott M
authors.initials: EM
authors.lastname: Antman
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D000077144:Clopidogrel; D023921:Coronary Stenosis / Q000150:complications / Q000628:therapy*; D003328:Coronary Thrombosis / Q000209:etiology / Q000517:prevention & control*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D000077542:Eptifibatide; D006470:Hemorrhage / Q000139:chemically induced; D007902:Length of Stay / Q000706:statistics & numerical data; D008565:Membrane Proteins / Q000037:antagonists & inhibitors; D010455:Peptides / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011292:Premedication; D058919:Purinergic P2 Receptor Antagonists; D016032:Randomized Controlled Trials as Topic; D058925:Receptors, Purinergic P2Y12; D012307:Risk Factors; D015607:Stents; D019851:Thrombophilia / Q000150:complications; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D008565:Membrane Proteins; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D058919:Purinergic P2 Receptor Antagonists; D058925:Receptors, Purinergic P2Y12; D000077144:Clopidogrel; D000077542:Eptifibatide; D013988:Ticlopidine; D001241:Aspirin